Ken Griffin’s Jade Biosciences JBIO Stock Holding History

Ken Griffin’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.93M	Buy	137,222 +101,167	+281%	+$1.46M	﹤0.01%	6137
2025 Q4	$556K	Buy	+36,055	New	+$423K	﹤0.01%	8771
2025 Q2	–	Sell	-899	Closed	-$79K	–	12502
2025 Q1	$79K	Buy	899 +740	+465%	+$65K	﹤0.01%	11780
2024 Q4	$14.7K	Buy	+159	New	+$13.7K	﹤0.01%	13394
2023 Q3	–	Sell	-8,341	Closed	-$5.01M	–	14266
2023 Q2	$5.01M	Buy	+8,341	New	+$5.33M	﹤0.01%	3645
2023 Q1	–	Sell	-44,626	Closed	-$45.8M	–	14688
2022 Q4	$45.8M	Sell	44,626 -1,533	-3%	-$1.11M	0.01%	1190
2022 Q3	$26.8M	Buy	46,159 +673	+1%	+$449K	0.01%	1597
2022 Q2	$24.9M	Sell	45,486 -39	-0.1%	-$18.6K	0.01%	1624
2022 Q1	$29.2M	Sell	45,525 -117	-0.3%	-$45.4K	0.01%	1579
2021 Q4	$18.8M	Buy	45,642 +76	+0.2%	+$38.4K	﹤0.01%	2099
2021 Q3	$32.4M	Sell	45,566 -577	-1%	-$323K	0.01%	1503
2021 Q2	$35.5M	Buy	+46,143	New	+$36.9M	0.01%	1434

Other funds holding JBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ken Griffin's JBIO Position: Q1 2026 in Review

Ken Griffin increased its Jade Biosciences (JBIO) stake by 281% in Q1 2026, buying an estimated $1.46M and bringing the position to 137,222 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #6137.

Ken Griffin first reported a position in JBIO in Q2 2021 and has held it in 12 quarters since. The position peaked at $45.8M in Q4 2022. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

Ken Griffin held 137,222 shares of Jade Biosciences worth $1.93M as of Q1 2026.
Ken Griffin bought 101,167 Jade Biosciences shares in Q1 2026, an estimated $1.46M.
Jade Biosciences made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #6137 holding.
Ken Griffin first reported a position in Jade Biosciences in Q2 2021 and has held it in 12 quarters since.
Ken Griffin's Jade Biosciences position peaked at $45.8M in Q4 2022.
120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.